The FIDELIO-DKD study showed that finerenone, a non-steroidal selective mineralocorticoid receptor antagonist, lowered the risks of CKD progression and cardiovascular events in people with CKD and type 2 diabetes treated optimally with renin-angiotensin system blockade. This evidence concerns the gene REN and chronic kidney disease.